Hudson Bay Leads USD102.8m Series C for US- and China-Based Biotech Harbour BioMed
Source(s): FinSMEs
Hudson Bay Capital led a USD102.8m Series C for US- and China-based biotech Harbour BioMed, with participation from Orbimed Asia, Country Garden VC, GTJA Investment Group, Octagon Capital, and Sage Partners, and follow-on from existing investor Greater Bay Area Investment Fund. Read more